Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
Objectives. To observe changes in blood glycemic variations and oxidative stress level before and after dapagliflozin treatment in patients with newly diagnosed T2DM. Methods. This was a randomized, double-blind, placebo-controlled, phase 3 trial. A total of 28 patients with newly diagnosed T2DM wit...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2016/5347262 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832545301745893376 |
|---|---|
| author | Feng-fei Li Gu Gao Qian Li Hong-hong Zhu Xiao-fei Su Jin-dan Wu Lei Ye Jian-hua Ma |
| author_facet | Feng-fei Li Gu Gao Qian Li Hong-hong Zhu Xiao-fei Su Jin-dan Wu Lei Ye Jian-hua Ma |
| author_sort | Feng-fei Li |
| collection | DOAJ |
| description | Objectives. To observe changes in blood glycemic variations and oxidative stress level before and after dapagliflozin treatment in patients with newly diagnosed T2DM. Methods. This was a randomized, double-blind, placebo-controlled, phase 3 trial. A total of 28 patients with newly diagnosed T2DM with HbA1c levels of 7.5–10.5% were randomly selected to receive dapagliflozin or placebo treatment for 24 weeks. After baseline data were collected, we analyzed glycemic variations and plasma 8-iso PGF2α level at baseline and at the endpoint. Primary outcome was the changes of mean amplitude glycemic excursion (MAGE) within groups. Results. After 24-week dapagliflozin therapy, our data showed the significant improvement of MAGE with dapagliflozin therapy (P=0.010). Compared with control group, patients in dapagliflozin group exhibited reduction in 24-hour MBG (P=0.026) and lower mean plasma glucose concentrations, especially during periods from 2400 to 0200 and 1300 to 1800 (P<0.05, resp.). In addition, plasma 8-iso PGF2α level was notably decreased in the treatment group compared to the control group (P=0.034). Conclusions. In conclusion, this study shows the ability of dapagliflozin to improve glycemic variations and associate with reduction of oxidative stress in patients with T2DM, which may benefit the cardiovascular system. |
| format | Article |
| id | doaj-art-48cb81cd31d3467fae9c7e94ebd9a479 |
| institution | Kabale University |
| issn | 2314-6745 2314-6753 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj-art-48cb81cd31d3467fae9c7e94ebd9a4792025-02-03T07:26:07ZengWileyJournal of Diabetes Research2314-67452314-67532016-01-01201610.1155/2016/53472625347262Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes MellitusFeng-fei Li0Gu Gao1Qian Li2Hong-hong Zhu3Xiao-fei Su4Jin-dan Wu5Lei Ye6Jian-hua Ma7Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaNational Heart Research Institute Singapore, National Heart Centre Singapore, SingaporeDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaObjectives. To observe changes in blood glycemic variations and oxidative stress level before and after dapagliflozin treatment in patients with newly diagnosed T2DM. Methods. This was a randomized, double-blind, placebo-controlled, phase 3 trial. A total of 28 patients with newly diagnosed T2DM with HbA1c levels of 7.5–10.5% were randomly selected to receive dapagliflozin or placebo treatment for 24 weeks. After baseline data were collected, we analyzed glycemic variations and plasma 8-iso PGF2α level at baseline and at the endpoint. Primary outcome was the changes of mean amplitude glycemic excursion (MAGE) within groups. Results. After 24-week dapagliflozin therapy, our data showed the significant improvement of MAGE with dapagliflozin therapy (P=0.010). Compared with control group, patients in dapagliflozin group exhibited reduction in 24-hour MBG (P=0.026) and lower mean plasma glucose concentrations, especially during periods from 2400 to 0200 and 1300 to 1800 (P<0.05, resp.). In addition, plasma 8-iso PGF2α level was notably decreased in the treatment group compared to the control group (P=0.034). Conclusions. In conclusion, this study shows the ability of dapagliflozin to improve glycemic variations and associate with reduction of oxidative stress in patients with T2DM, which may benefit the cardiovascular system.http://dx.doi.org/10.1155/2016/5347262 |
| spellingShingle | Feng-fei Li Gu Gao Qian Li Hong-hong Zhu Xiao-fei Su Jin-dan Wu Lei Ye Jian-hua Ma Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus Journal of Diabetes Research |
| title | Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus |
| title_full | Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus |
| title_fullStr | Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus |
| title_full_unstemmed | Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus |
| title_short | Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus |
| title_sort | influence of dapagliflozin on glycemic variations in patients with newly diagnosed type 2 diabetes mellitus |
| url | http://dx.doi.org/10.1155/2016/5347262 |
| work_keys_str_mv | AT fengfeili influenceofdapagliflozinonglycemicvariationsinpatientswithnewlydiagnosedtype2diabetesmellitus AT gugao influenceofdapagliflozinonglycemicvariationsinpatientswithnewlydiagnosedtype2diabetesmellitus AT qianli influenceofdapagliflozinonglycemicvariationsinpatientswithnewlydiagnosedtype2diabetesmellitus AT honghongzhu influenceofdapagliflozinonglycemicvariationsinpatientswithnewlydiagnosedtype2diabetesmellitus AT xiaofeisu influenceofdapagliflozinonglycemicvariationsinpatientswithnewlydiagnosedtype2diabetesmellitus AT jindanwu influenceofdapagliflozinonglycemicvariationsinpatientswithnewlydiagnosedtype2diabetesmellitus AT leiye influenceofdapagliflozinonglycemicvariationsinpatientswithnewlydiagnosedtype2diabetesmellitus AT jianhuama influenceofdapagliflozinonglycemicvariationsinpatientswithnewlydiagnosedtype2diabetesmellitus |